<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">25476811</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>08</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2014</Year>
        <Month>12</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1479-828X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>54</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Australian &amp; New Zealand journal of obstetrics &amp; gynaecology</Title>
          <ISOAbbreviation>Aust N Z J Obstet Gynaecol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>GnRH agonist trigger and a freeze-all strategy to prevent ovarian hyperstimulation syndrome: a retrospective study of OHSS risk and pregnancy rates.</ArticleTitle>
        <Pagination>
          <StartPage>581</StartPage>
          <EndPage>585</EndPage>
          <MedlinePgn>581-5</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/ajo.12277</ELocationID>
        <Abstract>
          <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To analyse the data from all controlled ovarian hyperstimulation antagonist cycles that used an agonist trigger and a freeze-all strategy to quantify the risk of ovarian hyperstimulation syndrome (OHSS) and subsequent pregnancy rates.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">A retrospective study of all women attending fertility clinics at IVF Australia, Sydney, undergoing controlled ovarian hyperstimulation (COH) using an antagonist protocol that had a subsequent gonadotropin-releasing hormone (GnRH) agonist trigger and freezing of all oocytes or embryos. The primary outcome measure was to determine the rate of OHSS. The secondary outcome measure was the clinical pregnancy rate.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">We collected data for 123 women. 25.2% were undergoing oocyte freezing and 74.8% underwent embryo freezing. There were no cases of OHSS, either early or late onset. The pregnancy rate was 31.7% after the first frozen cycle transfer with a cumulative pregnancy rate of 50% after two frozen embryo transfers.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results support the hypothesis that a GnRH agonist trigger and a freeze-all approach prevents OHSS with a good pregnancy rate.</AbstractText>
          <CopyrightInformation>Â© 2014 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Atkinson</LastName>
            <ForeName>Paul</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Reproductive Medicine Department, Royal Hospital for Women, Sydney, New South Wales, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Koch</LastName>
            <ForeName>Juliette</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ledger</LastName>
            <ForeName>William L</ForeName>
            <Initials>WL</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Australia</Country>
        <MedlineTA>Aust N Z J Obstet Gynaecol</MedlineTA>
        <NlmUniqueID>0001027</NlmUniqueID>
        <ISSNLinking>0004-8666</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005300">Fertility Agents, Female</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1X0094V6JV</RegistryNumber>
          <NameOfSubstance UI="D017274">Nafarelin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>33515-09-2</RegistryNumber>
          <NameOfSubstance UI="D007987">Gonadotropin-Releasing Hormone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9002-68-0</RegistryNumber>
          <NameOfSubstance UI="D005640">Follicle Stimulating Hormone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EFY6W0M8TG</RegistryNumber>
          <NameOfSubstance UI="D016729">Leuprolide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015925" MajorTopicYN="Y">Cryopreservation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004622" MajorTopicYN="Y">Embryo, Mammalian</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005300" MajorTopicYN="N">Fertility Agents, Female</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005307" MajorTopicYN="N">Fertilization in Vitro</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005640" MajorTopicYN="N">Follicle Stimulating Hormone</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007987" MajorTopicYN="N">Gonadotropin-Releasing Hormone</DescriptorName>
          <QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016729" MajorTopicYN="N">Leuprolide</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017274" MajorTopicYN="N">Nafarelin</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054315" MajorTopicYN="N">Oocyte Retrieval</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009865" MajorTopicYN="Y">Oocytes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016471" MajorTopicYN="N">Ovarian Hyperstimulation Syndrome</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010062" MajorTopicYN="N">Ovulation Induction</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018873" MajorTopicYN="N">Pregnancy Rate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">GnRH agonist trigger</Keyword>
        <Keyword MajorTopicYN="N">IVF/ICSI</Keyword>
        <Keyword MajorTopicYN="N">OHSS</Keyword>
        <Keyword MajorTopicYN="N">freeze-all</Keyword>
        <Keyword MajorTopicYN="N">pregnancy rate</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2014</Year>
          <Month>6</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2014</Year>
          <Month>9</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>12</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>12</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>8</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">25476811</ArticleId>
        <ArticleId IdType="doi">10.1111/ajo.12277</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
